The pharmaceutical company will replicate the investment it made in venture firm Remiges' $80m first fund, helping it to reach a target of $150m.

Pharmaceutical firm Taiho Pharmaceutical has agreed to supply up to $30m for the second venture capital fund to be formed by US-based cross-border VC firm Remiges Ventures. Remiges Ventures operates out of offices in the US and Japan, investing in early-stage developers of drugs for conditions with limited options for treatment. Its Remiges Biopharma Fund…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.